Body Composition and Physical Function Assessment for Childhood Cancer
Trial Summary
What is the purpose of this trial?
The primary objective of this study is to evaluate the feasibility and acceptability of obtaining repeated measurements of lean muscle mass, physical function, and biological aging in children receiving active cancer therapy. The secondary objective is to evaluate the feasibility of using the D3-creatine dilution method (D3Cr) to measure skeletal muscle mass in children with cancer. Assessments will be collected at diagnosis, once during active treatment, and end of treatment in coordination with routine imaging to monitor changes in study outcomes during active cancer treatment. Key sociodemographic, treatment and health-related factors will be abstracted from the medical record.
Will I have to stop taking my current medications?
The trial protocol does not specify whether you need to stop taking your current medications. It is best to discuss this with your treating physician, as their approval is required for participation.
What data supports the effectiveness of the treatment 30-second Sit-to-Stand (STS) and 6-Minute Walk Test (6MWT) for assessing physical function in children with cancer?
Is the 30-second Sit-to-Stand (STS) test safe for assessing physical performance?
How does this treatment for childhood cancer differ from other treatments?
This treatment is unique because it focuses on assessing body composition and physical function, which are often overlooked in traditional cancer treatments. It aims to systematically evaluate physical performance aspects like cardiorespiratory fitness, muscle strength, and flexibility, which are crucial for improving the quality of life in pediatric cancer patients.15101112
Research Team
Andrew Smitherman
Principal Investigator
UNC Lineberger Comprehensive Cancer Center
Eligibility Criteria
This trial is for children aged 8-21 with newly diagnosed malignant solid tumors or lymphoma, who are undergoing cancer treatment and can consent in English or Spanish. They must be approved by their treating physician to participate and able to undergo routine imaging like CT, MRI, or PET scans. It's not for those with a history of cancer treated only by surgery, planning palliative care, opting out of chemo/radiotherapy, diagnosed with leukemia, unable to consent, speaking other languages than English/Spanish or having conditions that prevent BIA assessment.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Diagnosis
Assessments collected at diagnosis to establish baseline measurements
Active Treatment
Participants receive active cancer therapy with repeated measurements of lean muscle mass, physical function, and biological aging
End of Treatment
Final assessments collected to monitor changes in study outcomes
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- 30-second Sit-to-Stand (STS)
- 6-Minute Walk Test (6MWT)
- Bioelectrical impedance Analysis (BIA)
- CT, MR and PET Imaging
- D3-Creatine Dilution (D3Cr)
- Hand Grip Strength (GS)
- PBTL p16 expression
- Timed Up and Go (TUG)
Find a Clinic Near You
Who Is Running the Clinical Trial?
UNC Lineberger Comprehensive Cancer Center
Lead Sponsor